Donald Nicholson

Donald Nicholson serves as Chairman of the Board of Directors for multiple biotechnology companies, including Muna Therapeutics, NodThera, Disc Medicine, and Jnana Therapeutics, with a focus on therapeutics for neurodegenerative disorders, systemic and CNS conditions, hematologic diseases, and oncology. Additionally, Donald Nicholson is a member of the Board of Directors for Generation Bio and previously held board positions at Kymera Therapeutics and Nimbus Therapeutics, where Donald also acted as Chief Executive Officer. With an extensive career at Merck, Donald Nicholson advanced through numerous leadership roles, culminating as Vice President of the Worldwide Discovery Head in various franchises. Educational qualifications include a Ph.D. in Biochemistry from Western University and postdoctoral studies in Molecular Cell Biology in Munich, Germany.